and well-being of children and youth
The Canadian Paediatric Society gives permission to print single copies of this document from our website. For permission to reprint or reproduce multiple copies, please see our copyright policy.
Scabies is a contagious skin infestation caused by a mite. It causes significant global morbidity, with an estimated 300 million cases annually. Although it can affect individuals at any socioeconomic level, individuals who live in poverty or in overcrowded conditions are at much higher risk for scabies. Lack of local expertise can result in failure to recognize scabies, leading to delayed diagnosis and inadequate treatment of cases and contacts. Scabies disproportionately affects many Indigenous (First Nations, Inuit, Métis) communities where risk factors are present. Scabies risk is also higher in young children, the elderly and immunocompromised individuals. Institutional outbreaks of scabies have also been reported. Apart from a very itchy rash, scabies can lead to secondary bacterial infections and related complications, as well as to stigmatization, depression, insomnia and significant financial costs. Topical antiscabies lotions are still the mainstay of treatment, but oral ivermectin has also proven effective under certain circumstances. Asymptomatic and symptomatic household members should all be treated at the same time. In Canada and globally, the presence of scabies is usually a symptom of poor living conditions and a sign that basic necessities need improvement. Clinicians who work with Indigenous communities can improve their ability to diagnose and treat scabies, and should advocate for better living conditions where scabies is prevalent.
Key Words: Crusted scabies; Indigenous communities; Infestations; Norwegian scabies; Poverty; Pruritus
Scabies is a contagious skin infestation that affects an estimated 300 million people around the world every year. While scabies can affect people at all socioeconomic levels, individuals who are young, elderly, immunocompromised or developmentally delayed are at significantly higher risk for scabies and related complications. Community-wide and institutional outbreaks have occurred in child care settings, long-term care facilities and prisons. Because scabies is associated with poverty, overcrowding, malnutrition and reduced access to health care, some Indigenous and resource-poor communities are disproportionately impacted. In some remote Australian Indigenous communities, the point prevalence of scabies approached 50%.
Because scabies is not a reportable disease in Canada, the epidemiology and real prevalence of this condition among Indigenous populations is not known. However, in the experience of health professionals working with Indigenous communities, scabies results in significant and under-recognized morbidity. Poverty, overcrowding, bed-sharing and families with many children are all factors that increase the risk of scabies spreading in some Indigenous communities. A lack of local expertise can lead to failure to recognize scabies, delays in diagnosis and inadequate treatment of cases and their contacts. A lack of clean running water may contribute to secondary skin infections and related complications. Improving living conditions and enhancing local health expertise will help reduce the burden of scabies in Indigenous communities.
Scabies is the result of an infestation with a mite, Sarcoptes scabiei, that is transmitted by direct skin-to-skin contact. Because the mite can only live away from human skin for a brief time (typically 24 h to 36 h), only limited transmission occurs through fomites, such as clothing and bed linen. The female adult mite burrows into the epidermis, depositing eggs over several days. The larvae hatch in approximately two to four days and take approximately 10 to 14 days to mature into adult mites. The infected individual develops a hypersensitive reaction to the mite, its eggs or its feces, which usually occurs approximately three weeks after the first exposure. With reinfestations, the immune response can be brisk, even as soon as the day after reinfection. The average adult infestation is approximately 10 to 15 adult female mites.
The classic presentation of scabies includes burrows, erythematous papules and generalized pruritus that is typically worse at night. Burrows are usually located between the fingers, in the flexure of the wrist, elbows or armpits, or on the genitals or breasts; however, they can sometimes be difficult to find. In infants and elderly individuals, burrows may be found on the head and neck, and can manifest as vesicles, pustules or nodules.
Scabies is often confused with other pruritic rashes such as eczema, impetigo, tinea corporis (ringworm) and psoriasis. For example, according to one study from Brazil, 18% to 43% of children diagnosed with eczema actually had scabies. Scratching frequently leads to secondary bacterial infections such as impetigo, pyoderma with Staphylococcus aureus and group A streptococcus. Complications of bacterial infections include poststreptococcal glomerulonephritis and cardiac disease. Furthermore, scabies can lead to stigmatization, depression, insomnia, and significant direct and indirect financial costs.
Crusted scabies (Norwegian scabies) is a rare condition caused by the host response to control the mite, resulting in hyperinfestation with millions of mites, severe inflammation and hyperkeratotic reaction. Approximately one-half of patients with crusted scabies do not report itching. Crusted scabies can occur in immunologically normal hosts, although it is more often associated with immunodeficiencies such as individuals with HIV, human T-lymphotropic virus 1, leukemia, T-cell lymphoma or autoimmune disease, as well as developmental delay and malnutrition. Crusted scabies is commonly misdiagnosed as psoriasis or eczema, especially when a topical steroid has already been used, and is more difficult to treat than classic scabies. Because of the burden of mites (potentially millions), crusted scabies is also more contagious than classic scabies and can cause significant outbreaks.
The clinical diagnosis of scabies is usually based on a history of pruritic rash that is typically worse at night and present in characteristic locations, especially with similar symptoms occurring in other household members. Although the presence of burrows often helps to establish the diagnosis, these are infrequently seen. Other ways to make a definitive diagnosis for scabies include:
All household contacts, even those without symptoms, must be treated simultaneously to avoid reinfestation and transmission. The main reason for treatment of household contacts is that scabies symptoms can take several weeks to appear, especially in new cases. In community-wide or institutional outbreaks, mass treatment should be considered. Typical treatment options for scabies are outlined in Table 1. Topical lotions are the mainstay of scabies treatment, although oral ivermectin has been used more recently in special circumstances. First-line treatment continues to be 5% permethrin cream or lotion, which is applied to the skin from neck to toes, usually for several hours – often overnight – then washed off. For infants, apply lotion to the face as well. Some products need to be reapplied after an interval of one to two weeks because they do not kill the mites’ eggs. In general, a retreatment in seven days improves efficacy. It is important to note that due to hypersensitivity, itching may persist or even increase over several weeks despite killing the mites and is not by itself evidence of persistent infection. However, the appearance of new lesions should be considered as a sign of persistent infection and a signal to retreat. Patients and their families should be warned of the possibility of persistent itching and an antihistamine or steroid may be considered as an adjunct to help relieve pruritus. Secondary bacterial infections need to be treated with topical or oral antibiotics, depending on severity.
Topical creams or lotions with 5% permethrin have low toxicity and excellent results but are relatively expensive compared with other treatments. A second treatment is usually given one week later to eliminate recently hatched eggs. Benzyl benzoate (28% for adults, and 10% to 12.5% for children) has high efficacy and a lower cost and is widely used outside of North America; it sometimes causes immediate skin irritation. Lindane (gamma benzene hexacholoride), an organochloride that has been withdrawn from the market in many parts of the world because of neurotoxicity concerns, is only considered when other therapies have failed. Sulphur precipitated in petroleum jelly has been used safely in young children and pregnant women, although its odour and messy application can compromise adherence to treatment.
While oral ivermectin has been shown to be effective in circumstances described below, this medication is not available in Canada except through Health Canada’s Special Access Programme. Ivermectin is a synthetic drug, which was discovered incidentally to have an impact on scabies during mass treatments for strongyloides and filiariasis. Although 5% permethrin continues to have higher efficacy according to studies, ivermectin has the advantage of being administered orally as a single dose, making treatment easier in some settings. Oral ivermectin has proven effective in managing institutional or community outbreaks, with rapid reduction of scabies symptoms. It has also been used very effectively in managing crusted scabies, especially with recurrent disease, and often in combination with keratolytics (to break down the keratin in the scales) or with topical 5% permethrin. Ivermectin’s use for scabies remains off-label but can be requested under Health Canada’s Special Access Programme (http://www.hc-sc.gc.ca/dhp-mps/acces/drugs-drogues/index-eng.php) for controlling outbreaks and crusted scabies therapy. Ivermectin is not approved for use in children weighing <15 kg, or in women who are pregnant or breastfeeding. Topical ivermectin may become a future treatment option but is not licensed for scabies management at this time.
|Scabies management in Canada|
|Treatment||Application period||Repeat||Age restrictions||Caution(s)||Other comments|
|5% permethrin cream
(Nix Dermal Cream*, Kwellada-P Lotion†)
|Leave on for 12–14 h, followed by bathing||7 days||>3 months of age||Consider as first-line
|10% crotamiton lotion/cream (Eurax Cream)||24 h||May be repeated in 24 h; wash off 48 h after last application||Skin irritation and contact dermatitis||Consider as second-line treatment|
precipitated in petroleum jelly (compounded)
|Daily for 3
|No||Safe in pregnancy
and for infants
|Effective but not commonly used due to messy application and odour|
|Benzyl benzoate 28% in adults, 10%–12.5% in children||24 h||May be repeated 1 day apart||Caution in pregnancy||Not available in North America but widely available elsewhere|
|1% Lindane cream||Apply 8–12 h for adults, 6–8 h for children, followed by bathing||Only if new mites or papules after 7 days of treatment||Use with caution in small children||Associated with neurotoxicity, ataxia, tremors and bone marrow suppression||Consider as second-line treatment only|
|Ivermectin (oral) for outbreak (Stromectol, Mectizan‡)||Single dose oral
|May need to be repeated in 2 weeks||Safety not established
in infants <15 kg, pregnant or lactating women
|Not licensed in Canada§|
|Ivermectin (oral) for crusted scabies (Stromectol, Mectizan‡)||Single dose oral
|Multiple repeat doses with keratolytics¶ and consider combination with 5% permethrin||Safety not established in infants <15 kg, pregnant or lactating women||Not licensed in Canada§|
|Read the product monographs before prescribing or applying any of these products. For information on coverage under Non-Insured Health Benefits Program, see <http://www.drugcoverage.ca/en-ca/Federal-Plans/non-insured-health-benefits>. *GlaxoSmithKline, USA. †MedTech Products, USA. ‡Merck and Co, USA. §Need to request through Health Canada’s Special Access Programme <www.hc-sc.gc.ca/dhp-mps/acces/drugs-drogues/index-eng.php>. ¶Keratolytics help remove keratin to allow better penetration of topical medications|
Scabies management must be clearly discussed with patients, their family and close contacts, as appropriate. Written instructions can be helpful, especially when provided in a family’s native language. Be sure to inform the family that even with appropriate treatment, symptoms may persist for several weeks. For an asymptomatic contact, explain that there may be a delay of three weeks between infestation and the appearance of symptoms, making whole-family/household treatment necessary to prevent further infection and spread.
The WHO considers scabies to be a neglected tropical disease with considerable disease burden worldwide. This designation may result in more research investigating scabies prevalence and control. In Canada, addressing underlying risk factors, such as poverty, overcrowding and lack of access to clean water, while improving access to health care, should help to reduce the burden of this disease in Indigenous communities. Plant derivatives may hold some promise as future scabies treatments, but have yet to be evaluated.
Scabies is a condition that disproportionately affects Indigenous communities in Canada, largely because of underlying living conditions. The Canadian Paediatric Society recommends that health professionals working with Indigenous communities:
The present position statement has been reviewed by the Infectious Diseases and Immunization, Community Paediatrics, and Drug Therapy and Hazardous Substances Committees of the Canadian Paediatric Society.
CPS FIRST NATIONS, INUIT AND MÉTIS HEALTH COMMITTEE
Members: Anna Banerji MD (past member); Roxanne Goldade MD (Board Representative); James Irvine MD; Radha Jetty MD;
Keith Menard MD; Sam Wong MD (Chair)
Liaisons: Halina Cyr, First Nations and Inuit Health Branch, Health Canada; James Jarvis MD, Committee on Native American Child Health; American Academy of Pediatrics; Lisa Monkman MD, Indigenous Physicians Association of Canada; Melanie Morningstar, Assembly of First Nations; Anna Claire Ryan, Inuit Tapiriit Kanatami; Eduardo Vides, Métis National Council; Cathy Winters, First Nations and Inuit Health Branch, Health Canada
Principal author: Anna Banerji MD
Disclaimer: The recommendations in this position statement do not indicate an exclusive course of treatment or procedure to be followed. Variations, taking into account individual circumstances, may be appropriate. Internet addresses are current at time of publication.